HCW Biologics Secures U.S. Patent Allowance for HCW9302 in Alopecia Areata
HCWB has more than doubled off its 52-week low of $1.5 on elevated volume (3.9× avg).
Summary
HCW Biologics received a Notice of Allowance from the USPTO for claims covering HCW9302 as an alopecia areata treatment, strengthening its patent estate alongside four recently issued patents. The company also reported its Phase 1 dose-escalating study remains on track for Q4 2026 completion, with no dose-limiting toxicities and encouraging preliminary responses in the first two dose cohorts. This follows a period of financial strain—Q2 loss widened to $5.2 million with only $741,324 in cash and a going-concern warning—making this clinical and IP progress a meaningful positive for the company's lead asset. The full Phase 1 readout expected in Q4 2026 will be the next key data point for investors.
At the time of this announcement, HCWB was trading at $3.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $1.50 to $36.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.